Interference No. 104,544 Paper149
McDonald v. Miyazaki Page 3
[4] The Miyazaki applications claim the benefit via 35 U.S.C. 119-121 to JP -76-39090,
filed 14 February 1994.
The counts
[5] There are two counts in this interference, count 3 and count 5.
[6] Count 3 is:
The method of McDonald claim 24 or Miyazaki 039 claim 74.
[7) McDonald claim 24 is:
24. The method of claim 22 131 wherein the active fragment is the C
terminal fragment.
[8] A polypeptide is formed by the covalent peptide bonding of the carboxyl group
(designated "C") of an a-amino acid to the a-amino group (designated "N") of another
a-amino acid. The C-terminus of a polypeptide is end of the peptide with the free
carboxyl group. The N-terminus is the end with the free amino group. By convention,
the amino-acid residues of a polypepticle are numbered from the N-terminus.
[9] Miyazaki 039 claim 74 is:
74. A method for increasing platelet production in an individual
comprising administering an effective amount of a thrombopoietin (TPC)
polypeptide having the biological activity of specifically stimulating and
increasing platelet production in combination with a pharmaceutically
acceptable carder, said TPO polypeptide selected from the group
3 McDonald claim 22: The method of claim 20 wherein the active fragment is selected from the group
consisting of the N-terminal and the C-terminal.
McDonald claim 20: A method of increasing platelet cell counts in a patient in need thereof which
comprises administering to the patient a therapeutic composition comprising a therapeutic amount of
thrombopoietin or an active fragment of thrombopoietin and a pharmaceutically acceptable carrier, said
therapeutic amount being sufficient to increase platelet cell counts in said patient by at least about 20% above
a baseline count.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007